PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30753572-2	2019	This study evaluated the mechanism of ceftazidime/avibactam resistance in a KPC-2-expressing Klebsiella pneumoniae isolated from a patient following ceftazidime/avibactam combination therapy with gentamicin for the treatment of ventilator-associated pneumonia.	Gentamicins	196-206	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	76-81	
24566172-1	2014	Gentamicin doses of 2 and 10 mug/ml were bactericidal against 64% and 100%, respectively, of gentamicin-susceptible KPC-2-producing Klebsiella pneumoniae strains.	Gentamicins	0-10	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	116-121	
24566172-1	2014	Gentamicin doses of 2 and 10 mug/ml were bactericidal against 64% and 100%, respectively, of gentamicin-susceptible KPC-2-producing Klebsiella pneumoniae strains.	Gentamicins	93-103	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	116-121	
22016687-5	2011	The KPC-2-producing isolate was resistant to all tested beta-lactams (including imipenem and meropenem), amikacin, tobramycin, ciprofloxacin, levofloxacin, and trimethoprim-sulfamethoxazole, but was susceptible to gentamicin, colistin, polymyxin B, and tigecycline.	Gentamicins	214-224	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	4-9